Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Wan Ip"'
Autor:
Sang Hyun Lim, Jamie Snider, Liron Birimberg‐Schwartz, Wan Ip, Joana C Serralha, Hugo M Botelho, Miquéias Lopes‐Pacheco, Madalena C Pinto, Mohamed Taha Moutaoufik, Mara Zilocchi, Onofrio Laselva, Mohsen Esmaeili, Max Kotlyar, Anna Lyakisheva, Priscilla Tang, Lucía López Vázquez, Indira Akula, Farzaneh Aboualizadeh, Victoria Wong, Ingrid Grozavu, Teuta Opacak‐Bernardi, Zhong Yao, Meg Mendoza, Mohan Babu, Igor Jurisica, Tanja Gonska, Christine E Bear, Margarida D Amaral, Igor Stagljar
Publikováno v:
Molecular Systems Biology, Vol 18, Iss 2, Pp 1-23 (2022)
Abstract Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a chloride and bicarbonate channel in secretory epithelia with a critical role in maintaining fluid homeostasis. Mutations in CFTR are associated with Cystic Fibrosis (CF), the mo
Externí odkaz:
https://doaj.org/article/2333634eb31448bfa35a483208141fd8
Autor:
Steven V Molinski, Saumel Ahmadi, Wan Ip, Hong Ouyang, Adriana Villella, John P Miller, Po‐Shun Lee, Kethika Kulleperuma, Kai Du, Michelle Di Paola, Paul DW Eckford, Onofrio Laselva, Ling Jun Huan, Leigh Wellhauser, Ellen Li, Peter N Ray, Régis Pomès, Theo J Moraes, Tanja Gonska, Felix Ratjen, Christine E Bear
Publikováno v:
EMBO Molecular Medicine, Vol 9, Iss 9, Pp 1224-1243 (2017)
Abstract The combination therapy of lumacaftor and ivacaftor (Orkambi®) is approved for patients bearing the major cystic fibrosis (CF) mutation: ΔF508. It has been predicted that Orkambi® could treat patients with rarer mutations of similar “th
Externí odkaz:
https://doaj.org/article/63e4048262714fd991511c4196c2fb6d
Autor:
Saumel Ahmadi, Zoltan Bozoky, Michelle Di Paola, Sunny Xia, Canhui Li, Amy P. Wong, Leigh Wellhauser, Steven V. Molinski, Wan Ip, Hong Ouyang, Julie Avolio, Julie D. Forman-Kay, Felix Ratjen, Jeremy A. Hirota, Johanna Rommens, Janet Rossant, Tanja Gonska, Theo J. Moraes, Christine E. Bear
Publikováno v:
npj Genomic Medicine, Vol 2, Iss 1, Pp 1-10 (2017)
Cystic fibrosis: toward personalized therapies A new method for evaluating drug responses in patient-derived respiratory tissue promises to help determine the best treatment for each patient with cystic fibrosis (CF). CF patients are highly susceptib
Externí odkaz:
https://doaj.org/article/7ad6ed4d84964bd982f178ae435366d1
Autor:
Huibi Cao, Hong Ouyang, Wan Ip, Kai Du, Wenming Duan, Julie Avolio, Jing Wu, Cathleen Duan, Herman Yeger, Christine E Bear, Tanja Gonska, Jim Hu, Theo J Moraes
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 2, Iss , Pp - (2015)
Cystic fibrosis (CF) results from mutations in the CF transmembrane conductance regulator (CFTR) gene, which codes for a chloride/bicarbonate channel in the apical epithelial membranes. CFTR dysfunction results in a multisystem disease including the
Externí odkaz:
https://doaj.org/article/98027c0e7a7e4df392f9c3f70e156406
Autor:
Liron Birimberg-Schwartz, Wan Ip, Claire Bartlett, Julie Avolio, Annelotte M Vonk, Tarini Gunawardena, Kai Du, Mohsen Esmaeili, Jeffrey M Beekman, Johanna Rommens, Lisa Strug, Christine E Bear, Theo J Moraes, Tanja Gonska
Publikováno v:
Life Science Alliance. 6:e202201857
Highly effective drugs modulating the defective protein encoded by the CFTR gene have revolutionized cystic fibrosis (CF) therapy. Preclinical drug-testing on human nasal epithelial (HNE) cell cultures and 3-dimensional human intestinal organoids (3D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16ef4274e2edae062d224ddad49590a8
https://doi.org/10.26508/lsa.202201857
https://doi.org/10.26508/lsa.202201857
Autor:
Gianni Panagiotou, Thomas S. Y. Chan, Paul P. Lee, Bonnie Kho, Sze-Fai Yip, Chi-Kuen Lau, Wa Li, Herbert Pang, Vivien Mak, Joycelyn Sim, Edmond S. K. Ma, Yok-Lam Kwong, Harold K. K. Lee, Rita Yim, Ho-Wan Ip, Raymond S.M. Wong, Albert K. W. Lie, Shek‐Yin Lin, Harinder Gill, June S. M. Lau, Jun Li, Chi-Chung Chan, Yu-Yan Hwang, Rock Y. Y. Leung, Garret M. K. Leung
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 10, Pp 3371-3382 (2020)
Cancer Medicine, Vol 9, Iss 10, Pp 3371-3382 (2020)
Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18‐ to 65‐year‐old AML patients refractory to first‐line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7 induction a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2e1b9bb7e961ef53889aeaa1c979d54
http://europepmc.org/articles/PMC7221314
http://europepmc.org/articles/PMC7221314
Autor:
Yu-Sheng Wu, Sunny Xia, Tanja Gonska, Michelle Di Paola, Mingyuan Li, Kai Du, Christine E. Bear, Julie D. Forman-Kay, Zoltán Bozóky, Alexandria Lew, Wan Ip, Saumel Ahmadi, Andrew Lloyd-Kuzik
Publikováno v:
American Journal of Respiratory Cell and Molecular Biology. 61:755-764
Rationale: SLC6A14 mediated L-arginine transport has been shown to augment the residual anion channel activity of the major mutant, F508del-CFTR, in the murine gastrointestinal tract. It is not yet...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a21ee361bbd345affe3ac0e1dcf3fab0
https://doi.org/10.1165/rcmb.2019-0094oc
https://doi.org/10.1165/rcmb.2019-0094oc
Autor:
Sunny Xia, Theo J. Moraes, Claire Bartlett, Janet Jiang, Leigh Wellhauser, Tanja Gonska, Yu-Sheng Wu, Hong Ouyang, Onofrio Laselva, Alexandria Lew, Wan Ip, Christine E. Bear, Saumel Ahmadi
Publikováno v:
Molecular Pharmacology. 96:515-525
ORKAMBI, a combination of the corrector, lumacaftor, and the potentiator, ivacaftor, partially rescues the defective processing and anion channel activity conferred by the major cystic fibrosis-causing mutation, F508del, in in vitro studies. Clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5243a55b077b06eb706b6c9c65c40c1e
https://doi.org/10.1124/mol.119.117143
https://doi.org/10.1124/mol.119.117143
Publikováno v:
The Lancet Oncology. 23:S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6004a49de7925c8b3aa7a1c234cd0eb0
https://doi.org/10.1016/s1470-2045(22)00406-5
https://doi.org/10.1016/s1470-2045(22)00406-5
Autor:
Richard Y. Wu, Hiromu Miyake, George Biouss, Carol Lee, Tanja Gonska, Dorothy Lee, Agostino Pierro, Sinobol Chuslip, Bo Li, Wan Ip, Yuhki Koike
Publikováno v:
The FASEB Journal. 35
Necrotizing enterocolitis (NEC) is one of the most severe gastrointestinal diseases affecting premature infants. It has been shown that NEC is associated with disrupted intestinal barrier and dysregulated endoplasmic reticulum (ER)-stress response. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b229476c59543e361c093eddb6ffee
https://doi.org/10.1096/fj.202001426r
https://doi.org/10.1096/fj.202001426r